...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Fertility and Sterility: Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society >Use of preimplantation genetic diagnosis and preimplantation genetic screening in the United States: a Society for Assisted Reproductive Technology Writing Group paper.
【24h】

Use of preimplantation genetic diagnosis and preimplantation genetic screening in the United States: a Society for Assisted Reproductive Technology Writing Group paper.

机译：植入前遗传学诊断和植入前遗传学筛查在美国的应用：辅助生殖技术学会写作小组论文。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To comprehensively report Society for Assisted Reproductive Technology (SART) member program usage of preimplantation genetic testing (PGT), preimplantation genetic diagnosis (PGD) for diagnosis of specific conditions, and preimplantation genetic screening for aneuploidy (PGS). DESIGN: Retrospective study. SETTING: United States SART cohort data. PATIENT(S): Women undergoing a PGT cycle in which at least one embryo underwent biopsy. INTERVENTION(S): PGT. MAIN OUTCOME MEASURE(S): PGT use, indications, and delivery rates. RESULT(S): Of 190,260 fresh, nondonor assisted reproductive technology (ART) cycles reported to SART CORS in 2007-2008, 8,337 included PGT. Of 6,971 cycles with a defined indication, 1,382 cycles were for genetic diagnosis, 3,645 for aneuploidy screening (PGS), 527 for translocation, and 1,417 for elective sex election. Although the total number of fresh, autologous cycles increased by 3.6% from 2007 to 2008, the percentage of cycles with PGT decreased by 5.8% (4,293 in 2007 and 4,044 in 2008). As a percentage of fresh, nondonor ART cycles, use dropped from 4.6% (4,293/93,433) in 2007 to 4.2% (4,044/96,827) in 2008. The primary indication for PGT was PGS: cycles performed for this indication decreased (-8.0%). PGD use for single-gene defects (+3.2%), elective sex selection (+5.3%), and translocation analysis (+0.5%) increased. PGT usage varied significantly by geographical region. CONCLUSION(S): PGT usage in the United States decreased between 2007 and 2008 owing to a decrease in PGS. Use of elective sex selection increased. High transfer cancellation rates correlated with reduced live-birth rates for some PGT indications.
机译：目的：全面报告辅助生殖技术协会（SART）会员计划使用的植入前基因检测（PGT），植入前基因诊断（PGD）诊断特定情况以及植入前基因筛查非整倍性（PGS）。设计：回顾性研究。地点：美国SART队列数据。患者：经历PGT循环的妇女，其中至少一个胚胎接受了活检。干预：PGT。主要观察指标：PGT的使用，指示和交付率。结果：在2007-2008年向SART CORS报告的190,260个新鲜的，非供体辅助的生殖技术（ART）周期中，有8,337个包括PGT。在具有定义指示的6,971个周期中，有1,382个周期用于遗传诊断，3,645个用于非整倍性筛选（PGS），527个用于易位，而1,417个用于择性选举。尽管从2007年到2008年，新鲜的自体循环总数增加了3.6％，但带有PGT的循环百分比却下降了5.8％（2007年为4,293，2008年为4,044）。作为新的非供体ART周期的百分比，使用量从2007年的4.6％（4,293 / 93,433）下降到2008年的4.2％（4,044 / 96,827）。PGT的主要指征是PGS：为此指征执行的周期减少了（-8.0 ％）。 PGD​​用于单基因缺陷（+ 3.2％），选择性性别选择（+ 5.3％）和易位分析（+ 0.5％）的使用增加了。 PGT的使用情况因地理区域而异。结论：由于PGS的减少，美国PGT的使用在2007年至2008年之间减少。选修性别选择的使用增加。某些PGT适应症的高转移取消率与活产率降低相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号